283 related articles for article (PubMed ID: 12963489)
21. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
22. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
[TBL] [Abstract][Full Text] [Related]
23. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Date I; Felten DL; Felten SY
Brain Res; 1990 Jun; 519(1-2):266-76. PubMed ID: 1975765
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
Smith TS; Trimmer PA; Khan SM; Tinklepaugh DL; Bennett JP
Brain Res; 1997 Aug; 765(2):189-97. PubMed ID: 9313891
[TBL] [Abstract][Full Text] [Related]
26. Dopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
Chen Y; Ni YY; Liu J; Lu JW; Wang F; Wu XL; Gu MM; Lu ZY; Wang ZG; Ren ZH
BMC Neurosci; 2013 Jul; 14():76. PubMed ID: 23902361
[TBL] [Abstract][Full Text] [Related]
27. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
Kuhlmann AC; Guilarte TR
Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
[TBL] [Abstract][Full Text] [Related]
28. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
Li C; Biswas S; Li X; Dutta AK; Le W
J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
[TBL] [Abstract][Full Text] [Related]
29. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
31. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter.
Gainetdinov RR; Fumagalli F; Jones SR; Caron MG
J Neurochem; 1997 Sep; 69(3):1322-5. PubMed ID: 9282960
[TBL] [Abstract][Full Text] [Related]
32. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression.
Hung HC; Lee EH
Brain Res Mol Brain Res; 1996 Sep; 41(1-2):14-26. PubMed ID: 8883930
[TBL] [Abstract][Full Text] [Related]
33. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
Quik M; Police S; He L; Di Monte DA; Langston JW
Neuroscience; 2000; 98(2):263-73. PubMed ID: 10854757
[TBL] [Abstract][Full Text] [Related]
34. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
35. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
Ishiwata K; Koyanagi Y; Abe K; Kawamura K; Taguchi K; Saitoh T; Toda J; Senda M; Sano T
J Neurochem; 2001 Nov; 79(4):868-76. PubMed ID: 11723179
[TBL] [Abstract][Full Text] [Related]
37. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice.
Sundström E; Strömberg I; Tsutsumi T; Olson L; Jonsson G
Brain Res; 1987 Mar; 405(1):26-38. PubMed ID: 2882814
[TBL] [Abstract][Full Text] [Related]
38. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
Neuropharmacology; 1989 Nov; 28(11):1211-6. PubMed ID: 2512516
[TBL] [Abstract][Full Text] [Related]
39. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.
Quik M; Sum JD; Whiteaker P; McCallum SE; Marks MJ; Musachio J; McIntosh JM; Collins AC; Grady SR
Mol Pharmacol; 2003 May; 63(5):1169-79. PubMed ID: 12695545
[TBL] [Abstract][Full Text] [Related]
40. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
